[go: up one dir, main page]

MA49207B1 - Muteines d'interleukine 2 pour la propagation de lymphocytes t regulateurs - Google Patents

Muteines d'interleukine 2 pour la propagation de lymphocytes t regulateurs

Info

Publication number
MA49207B1
MA49207B1 MA49207A MA49207A MA49207B1 MA 49207 B1 MA49207 B1 MA 49207B1 MA 49207 A MA49207 A MA 49207A MA 49207 A MA49207 A MA 49207A MA 49207 B1 MA49207 B1 MA 49207B1
Authority
MA
Morocco
Prior art keywords
cells
muteins
relates
present
regulatory
Prior art date
Application number
MA49207A
Other languages
English (en)
Other versions
MA49207A1 (fr
Inventor
Marc A Gavin
Gunasekaran Kannan
Li Li
Joshua T Pearson
Margaret Karow
Snahel Patel
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA49207A1 publication Critical patent/MA49207A1/fr
Publication of MA49207B1 publication Critical patent/MA49207B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des mutéines d'il-2 et des molécules de fusion fc mutéine d'il-2 qui propagent et activent de préférence des lymphocytes t régulateurs et peuvent faire l'objet d'une production à grande échelle. La présente invention concerne également des variantes de molécules fc d'igg1 humaines dépourvues ou ayant une fonction effectrice fortement réduite et une stabilité élevée malgré l'absence de glycosylation à n297. La présente invention concerne également des peptides lieurs qui sont glycosylés lorsqu'ils sont exprimés dans des cellules de mammifère.
MA49207A 2013-03-14 2015-10-09 Muteines d'interleukine 2 pour la propagation de lymphocytes t regulateurs MA49207B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784669P 2013-03-14 2013-03-14
PCT/US2014/029111 WO2014153111A2 (fr) 2013-03-14 2014-03-14 Mutéines d'interleukine 2 pour la propagation de lymphocytes t régulateurs

Publications (2)

Publication Number Publication Date
MA49207A1 MA49207A1 (fr) 2021-09-30
MA49207B1 true MA49207B1 (fr) 2022-08-31

Family

ID=50680166

Family Applications (2)

Application Number Title Priority Date Filing Date
MA38477A MA38477B1 (fr) 2013-03-14 2014-03-14 Mutéines d'interleukine 2 pour la propagation de lymphocytes t régulateurs
MA49207A MA49207B1 (fr) 2013-03-14 2015-10-09 Muteines d'interleukine 2 pour la propagation de lymphocytes t regulateurs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA38477A MA38477B1 (fr) 2013-03-14 2014-03-14 Mutéines d'interleukine 2 pour la propagation de lymphocytes t régulateurs

Country Status (40)

Country Link
US (8) US9546203B2 (fr)
EP (2) EP2970441B1 (fr)
JP (6) JP6480409B2 (fr)
KR (5) KR102219124B1 (fr)
CN (2) CN105358570B (fr)
AP (1) AP2015008737A0 (fr)
AR (1) AR095541A1 (fr)
AU (2) AU2014236316B2 (fr)
BR (1) BR112015022440B1 (fr)
CA (3) CA2905141A1 (fr)
CL (2) CL2015002686A1 (fr)
CR (2) CR20200004A (fr)
CY (2) CY1121767T1 (fr)
DK (2) DK2970423T3 (fr)
EA (2) EA034326B1 (fr)
ES (2) ES2737598T3 (fr)
HR (2) HRP20190970T1 (fr)
HU (2) HUE044321T2 (fr)
IL (2) IL241349B (fr)
JO (1) JO3796B1 (fr)
LT (2) LT2970441T (fr)
MA (2) MA38477B1 (fr)
ME (2) ME03437B (fr)
MX (2) MX366854B (fr)
MY (2) MY172991A (fr)
NZ (1) NZ751148A (fr)
PE (1) PE20151763A1 (fr)
PH (1) PH12015502051B1 (fr)
PL (2) PL2970441T3 (fr)
PT (2) PT2970423T (fr)
RS (2) RS58854B1 (fr)
SG (2) SG11201507574VA (fr)
SI (2) SI2970423T1 (fr)
SM (2) SMT201900301T1 (fr)
TN (1) TN2015000416A1 (fr)
TR (2) TR201908362T4 (fr)
TW (3) TWI709572B (fr)
UA (1) UA119140C2 (fr)
UY (2) UY40090A (fr)
WO (2) WO2014153063A1 (fr)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9926366B2 (en) * 2012-10-04 2018-03-27 Novelmed Therapeutics, Inc. Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
US10160793B2 (en) 2013-03-15 2018-12-25 Genentech, Inc. Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteins
AU2014228924B2 (en) 2013-03-15 2019-04-18 Amgen Inc. Human PAC1 antibodies
NZ719654A (en) 2014-02-06 2020-06-26 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof
CN114133456A (zh) * 2014-07-21 2022-03-04 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的分子
CN113234138A (zh) 2014-08-11 2021-08-10 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
EP3194435A1 (fr) 2014-09-15 2017-07-26 Amgen Inc. Protéines de liaison antigéniques bispécifiques anti-récepteur cgrp/récepteur pac1 et leurs utilisations
EP3875152B1 (fr) 2014-12-15 2024-04-10 Washington University Compositions et méthodes pour l'administration ciblée de cytokines
PH12017501856B1 (en) * 2015-04-10 2022-08-10 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
CR20170510A (es) 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
US11591382B2 (en) 2015-09-22 2023-02-28 Genentech, Inc. Expression of Fc-containing proteins
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
HUE057220T2 (hu) * 2016-02-03 2022-04-28 Amgen Res Munich Gmbh BCMA és CD3 bispecifikus, T-sejtet kötõ antitest-konstrukciók
US10781264B2 (en) * 2016-02-03 2020-09-22 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs
CN109071679B (zh) 2016-02-05 2023-07-28 华盛顿大学 用于靶向的细胞因子递送的组合物和方法
CN107287273B (zh) * 2016-03-31 2021-03-09 复旦大学附属妇产科医院 表达Tim-3的外周血NK细胞在制备自然流产生物标记物中的用途
WO2017180587A2 (fr) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Systèmes de biocircuits régulés
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
JP7206190B2 (ja) 2016-06-22 2023-01-17 ダヴィド・クラッツマン 遺伝的に修飾されたｔリンパ球
WO2018027025A1 (fr) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Agent liant cd40 et utilisations associées
KR101928981B1 (ko) 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
MX2019005400A (es) 2016-11-08 2019-08-05 Delinia Inc Variantes de il-2 para el tratamiento de enfermedades autoinmunes.
WO2018106885A1 (fr) 2016-12-07 2018-06-14 East Carolina University Compositions et méthodes de culture et/ou de croissance in vitro de lymphocytes t régulateurs
US10961310B2 (en) 2017-03-15 2021-03-30 Pandion Operations, Inc. Targeted immunotolerance
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
SG11201909949XA (en) * 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
MX2020003549A (es) 2017-10-04 2020-08-03 Amgen Inc Fusiones de transtiretina e inmunoglobulina.
MX2020005041A (es) 2017-11-21 2020-10-12 Univ Leland Stanford Junior Agonistas parciales de interleucina-2.
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
JP2021505156A (ja) * 2017-12-06 2021-02-18 パンディオン・オペレーションズ・インコーポレイテッド 標的化免疫寛容
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN118515780A (zh) * 2017-12-06 2024-08-20 潘迪恩运营公司 Il-2突变蛋白及其用途
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
CN111868079B (zh) * 2017-12-27 2025-06-17 协和麒麟株式会社 Il-2变体
AU2019207915B2 (en) * 2018-01-12 2025-09-04 Amgen Inc. PAC1 antibodies and uses thereof
EP3746095A4 (fr) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Procédé de production de cellules tueuses naturelles et composition pour le traitement du cancer
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
MX2020009975A (es) * 2018-03-28 2020-10-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
AU2019283621B2 (en) 2018-06-07 2023-03-30 Korea Research Institute Of Bioscience And Biotechnology Transgenic mouse for aglycosylated antibody production and use of aglycosylated antibody produced therefrom
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CA3102829A1 (fr) 2018-06-22 2019-12-26 Cugene Inc. Variants d'interleukine-2 et leurs procedes d'utilisation
CN120424233A (zh) 2018-06-22 2025-08-05 科优基因公司 基于细胞因子的可生物活化药物及其使用方法
CN112584859A (zh) 2018-07-02 2021-03-30 美国安进公司 抗steap1抗原结合蛋白
WO2020007937A1 (fr) 2018-07-03 2020-01-09 Iltoo Pharma Utilisation de l'interleukine-2 pour le traitement de la sclérose systémique
WO2020035482A1 (fr) 2018-08-13 2020-02-20 Iltoo Pharma Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
CN111138542B (zh) 2018-11-01 2022-09-23 山东新时代药业有限公司 双特异性抗体及其用途
EP3920899A2 (fr) 2019-02-08 2021-12-15 The UAB Research Foundation Composition pour le traitement et la prévention de la maladie inflammatoire chronique de l'intestin
EP3924379A4 (fr) 2019-02-15 2022-12-21 Integral Molecular, Inc. Anticorps comprenant une chaîne légère commune et leurs utilisations
MX2021009831A (es) 2019-02-15 2021-09-10 Integral Molecular Inc Anticuerpos claudina 6 y usos de los mismos.
IL286711B2 (en) * 2019-03-29 2025-10-01 Inst Curie Interleukin 2 variants with different biological activities
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
WO2020236875A1 (fr) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Immunotolérance ciblée madcam
EP3980051A4 (fr) * 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. Fusions de polypeptides d'interleukine-2 mutants avec des molécules de liaison à l'antigène pour moduler la fonction de cellules immunitaires
MA56120A (fr) 2019-06-07 2022-04-13 Amgen Inc Constructions de liaison bispécifiques
US20220324924A1 (en) 2019-07-08 2022-10-13 Amgen Inc. Multispecific transthyretin immunoglobulin fusions
US12084484B2 (en) * 2019-07-26 2024-09-10 Visterra, Inc. Interleukin-2 agents and uses thereof
CN114222764B (zh) * 2019-08-12 2025-03-11 奥美药业有限公司 可优先结合IL-2Rα的IL-2融合蛋白
MX2022001866A (es) * 2019-08-13 2022-03-11 Amgen Inc Muteinas de interleucina-2 para la expansion de celulas t reguladoras.
BR112022004590A2 (pt) 2019-09-13 2022-06-14 Kyowa Kirin Co Ltd Variante dcr3
EP4017542A1 (fr) 2019-10-04 2022-06-29 Tae Life Sciences Compositions d'anticorps comprenant des mutations de fc et ayant des propriétés de conjugaison spécifiques à un site
AU2020389422B2 (en) * 2019-11-20 2024-08-08 Gi Cell, Inc. Medium composition for culturing T cells and method for culturing T cells using same
CN114929249A (zh) * 2019-11-29 2022-08-19 Nkmax有限公司 产生自然杀伤细胞及其组合物的方法
EP4073094A1 (fr) 2019-12-12 2022-10-19 Iltoo Pharma Constructions chimériques d'interleukine 2
WO2021127262A1 (fr) 2019-12-17 2021-06-24 Amgen Inc. Double agoniste de l'interleukine-2/ récepteur du tnf destiné à être utilisé en thérapie
MX2022007754A (es) 2019-12-20 2022-07-19 Regeneron Pharma Nuevos agonistas de il2 y metodos de uso de estos.
MX2022008771A (es) 2020-01-14 2022-10-07 Synthekine Inc Metodos y composiciones de muteinas de il2 sesgadas.
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
JP2023518434A (ja) * 2020-03-19 2023-05-01 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド インターロイキン２変異体およびその使用
WO2021185362A1 (fr) * 2020-03-19 2021-09-23 信达生物制药(苏州)有限公司 Mutant de l'interleukine-2 et son utilisation
US12049488B2 (en) * 2020-04-06 2024-07-30 Lung Biotechnology Pbc Modular synthetic receptors and methods of use
CN116323647A (zh) 2020-05-13 2023-06-23 博纳姆治疗公司 蛋白质复合物的组合物及其使用方法
AU2021283933A1 (en) 2020-06-04 2023-01-05 Amgen Inc. Bispecific binding constructs
US20230226203A1 (en) * 2020-06-18 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN112048018B (zh) * 2020-08-31 2021-10-08 南方医科大学 一种嵌合t细胞生长因子及其应用
JP7583155B2 (ja) 2020-09-04 2024-11-13 山▲東▼先声生物制▲薬▼有限公司 Ｉｌ－２変異体およびその用途
KR20230097094A (ko) 2020-10-29 2023-06-30 브리스톨-마이어스 스큅 컴퍼니 질환의 치료를 위한 융합 단백질
CA3203468A1 (fr) 2020-12-03 2022-06-09 Amgen Inc. Constructions d'immunoglobulines a domaines de liaison multiples
EP4255466A1 (fr) 2020-12-04 2023-10-11 Visterra, Inc. Procédés d'utilisation d'agents d'interleukine-2
CA3201656A1 (fr) * 2020-12-10 2022-06-16 Joint Stock Company "Biocad" Immunocytokine pour activer le recepteur il-10ra humain et son utilisation
KR20230124030A (ko) * 2020-12-23 2023-08-24 머크 샤프 앤드 돔 엘엘씨 자가면역 및 염증성 질환을 치료하기 위한 il-2 뮤테인
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
IL308609A (en) 2021-05-19 2024-01-01 Asher Biotherapeutics Inc IL-21 polypeptides and target constructs
TW202306584A (zh) 2021-05-27 2023-02-16 法商賽諾菲公司 具有對Fc受體之增強親和力及改良熱穩定性的Fc變體
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
EP4370139A4 (fr) 2021-07-14 2025-10-15 Synthekine Inc Méthodes et compositions destinées à être utilisées dans la thérapie cellulaire contre la maladie néoplasique
AU2022324624A1 (en) * 2021-08-06 2024-02-08 Amgen Inc. Isolation of therapeutic protein
CN118414160A (zh) 2021-10-06 2024-07-30 艾尔图制药公司 对发炎组织具有靶向特异性的白介素2嵌合构建体
AU2022364888A1 (en) * 2021-10-14 2024-05-30 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
CA3234966A1 (fr) 2021-10-14 2023-04-20 Teneobio, Inc. Proteines de liaison a la mesotheline et leurs utilisations
CN120131911A (zh) * 2021-12-01 2025-06-13 威特拉公司 使用白细胞介素-2药剂的方法
EP4476250A1 (fr) 2022-02-07 2024-12-18 Vib Vzw Stabilisation modifiée de régions fc aglycosylées
WO2023164476A2 (fr) * 2022-02-22 2023-08-31 The Regents Of The University Of Michigan Compositions et méthodes de traitement de troubles auto-immuns
WO2023165553A1 (fr) * 2022-03-03 2023-09-07 海南先声药业有限公司 Composition pharmaceutique de protéine de fusion de bloc fc d'anticorps-mutant il2 et son utilisation
EP4499846A1 (fr) 2022-03-25 2025-02-05 Universität Zürich Ciblage induit par adenovirus de cellules immunitaires activees
WO2023227790A1 (fr) 2022-05-27 2023-11-30 Sanofi Agents d'activation de cellules tueuses naturelles (nk) se liant aux variants nkp46 et bcma avec ingénierie de fc
JP2025524899A (ja) 2022-07-27 2025-08-01 テネオバイオ， インコーポレイテッド メソテリン結合タンパク質及びその使用
CA3265946A1 (fr) 2022-09-12 2024-03-21 Sorbonne Universite Interleukine-2 pour le traitement des troubles du spectre autistique
WO2024077044A1 (fr) 2022-10-05 2024-04-11 Amgen Inc. Polythérapies comprenant des thérapies de redirection de lymphocytes t et des anticorps agonistes anti-il-2r ou des fragments de ceux-ci
EP4608859A1 (fr) 2022-10-25 2025-09-03 Ablynx N.V. Polypeptides variants fc glycomodifiés à fonction effectrice améliorée
KR20250114330A (ko) 2022-11-30 2025-07-29 인테그럴 몰큘러 인코포레이티드 클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식
EP4648792A2 (fr) 2023-01-09 2025-11-19 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène anti-tnfr2 et leurs utilisations
CN121079323A (zh) 2023-02-21 2025-12-05 特尼奥生物股份有限公司 c-Kit结合蛋白、嵌合抗原受体及其用途
AR133427A1 (es) 2023-07-31 2025-09-24 Sanofi Sa Anticuerpos anti-gprc5d y composiciones
WO2025049858A1 (fr) 2023-09-01 2025-03-06 Amgen Inc. Molécules pour le traitement du cancer
WO2025096842A2 (fr) 2023-11-03 2025-05-08 Amgen Inc. Molécules de ciblage de fibroblastes
WO2025096843A1 (fr) 2023-11-03 2025-05-08 Amgen Inc. Molécules bispécifiques
WO2025106529A2 (fr) * 2023-11-14 2025-05-22 Cavalry Biosciences, Inc. Compositions destinées au ciblage de cellules musculaires et leurs utilisations
WO2025133290A1 (fr) 2023-12-21 2025-06-26 Temper Bio Protéine pour la régulation immunitaire
WO2025149633A1 (fr) 2024-01-12 2025-07-17 Laigo Bio B.V. Protéines bispécifiques de liaison à l'antigène
WO2025217101A2 (fr) 2024-04-09 2025-10-16 Amgen Inc. Anticorps agonistes à chaîne lourde anti-il-2rbg
WO2025217240A1 (fr) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Protéines de liaison à l'antigène anti-tnfr2 et leurs utilisations
US20260028384A1 (en) 2024-04-17 2026-01-29 Visterra, Inc. Use of il-2 variant for treating kidney transplant rejection
WO2025259515A2 (fr) 2024-06-11 2025-12-18 Amgen Inc. Polythérapie
WO2026006809A1 (fr) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Molécules multispécifiques se liant à tnfr2 et cd25 et leurs utilisations
WO2026022712A1 (fr) 2024-07-23 2026-01-29 Sanofi Modulateur de ligase céréblon et polythérapie d'activation de cellules nk bcma

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447A (en) 1846-04-04 Car- wheel
US233A (en) 1837-06-14 Improvement in plows
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (fr) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Procede de fixation d'une proteine sur un substrat
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (fr) 1977-02-17 1981-01-20 Hideo Hirohara Traduction non-disponible
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0351410A1 (fr) 1987-03-18 1990-01-24 3i RESEARCH EXPLOITATION LIMITED Peptide de liaison de complement
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
WO1991018982A1 (fr) 1990-06-05 1991-12-12 Immunex Corporation Recepteurs de l'interleukine-1 de type ii
CA2062582C (fr) 1991-03-27 1996-03-26 Tse-Wen Chang Methodes et substances pour recruter des agents therapeutiques a des tissus solides
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
FR2752462B1 (fr) 1996-08-14 1998-10-23 Essilor Int Procede d'incorporation d'additifs dans un article ophtalmique au moyen d'un fluide a l'etat supercritique
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
EP1117815A1 (fr) 1998-09-29 2001-07-25 Pioneer Hi-Bred International Inc. Elements mar/sar flanquant une construction dictee par rsyn7
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
IL155812A0 (en) * 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
AU2002216443A1 (en) 2000-12-15 2002-06-24 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fointerferon beta
CA2435972C (fr) 2001-01-26 2011-09-13 University Of Lausanne Regions se liant a la matrice nucleaire (mar) et procedes d'utilisation de celles-ci
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
MXPA05013565A (es) * 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
CA2557677A1 (fr) 2004-03-05 2005-10-06 Chiron Corporation Systeme de tests in vitro permettant de predire la tolerabilite d'agents therapeutiques chez des patients
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
US7521541B2 (en) * 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
PT2650020T (pt) * 2005-05-06 2016-12-12 Providence Health & Services - Oregon Proteína de fusão de imunoglobulina ox-40 trimérica e métodos do campo de utilização
EP1909831A4 (fr) 2005-06-14 2013-02-20 Amgen Inc Préparations de protéines à tamponnage spontané
CA2614766A1 (fr) * 2005-07-11 2007-01-18 Macrogenics, Inc. Methodes de traitement d'une maladie auto-immune au moyen d'anticorps anti-cd16a humanises
WO2008112325A2 (fr) 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Traitement de troubles auto-immuns
GB0623539D0 (en) 2006-11-24 2007-01-03 Avidex Ltd Polypeptides
US20090016935A1 (en) 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
EP2389192A4 (fr) * 2009-01-23 2013-01-16 Biogen Idec Inc Polypeptides fc stabilisés avec une fonction effectrice réduite et procédés d'utilisation
CA2781539C (fr) 2009-11-23 2021-07-20 Amgen Inc. Anticorps monomere fc
US20130011401A1 (en) * 2009-12-22 2013-01-10 Novartis Ag Soluble proteins for use as therapeutics
US20120171120A1 (en) 2010-11-30 2012-07-05 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
PL3489255T3 (pl) * 2011-02-10 2021-11-22 Roche Glycart Ag Zmutowane polipeptydy interleukiny-2
US20140112926A1 (en) 2011-03-16 2014-04-24 Amgen Inc. Fc VARIANTS
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2794653B1 (fr) 2011-12-23 2019-03-13 Pfizer Inc Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
CN104093740B (zh) 2012-02-06 2018-01-09 弗·哈夫曼-拉罗切有限公司 使用csf1r抑制剂的组合物和方法
KR102031317B1 (ko) 2012-05-21 2019-10-14 제넨테크, 인크. 혈액-뇌 장벽 수송의 안전성을 개선하는 방법
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
US10160793B2 (en) * 2013-03-15 2018-12-25 Genentech, Inc. Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteins
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
AU2014236316A9 (en) 2018-11-08
CN105143253B (zh) 2021-02-19
WO2014153111A2 (fr) 2014-09-25
AU2014236281A1 (en) 2015-09-24
SI2970441T1 (sl) 2019-07-31
RS58854B1 (sr) 2019-07-31
NZ712066A (en) 2021-05-28
MY172991A (en) 2019-12-17
MY202248A (en) 2024-04-19
CR20150557A (es) 2015-11-10
ME03437B (fr) 2020-01-20
JP2021040630A (ja) 2021-03-18
TWI784288B (zh) 2022-11-21
US10562950B2 (en) 2020-02-18
US11976102B2 (en) 2024-05-07
HRP20191075T1 (hr) 2019-09-20
EA034326B1 (ru) 2020-01-28
JO3796B1 (ar) 2021-01-31
DK2970423T3 (da) 2019-07-08
EP2970423A2 (fr) 2016-01-20
AR095541A1 (es) 2015-10-21
TR201910802T4 (tr) 2019-08-21
ES2720225T3 (es) 2019-07-18
JP6450365B2 (ja) 2019-01-09
US20180319859A1 (en) 2018-11-08
PL2970441T3 (pl) 2019-09-30
US9580486B2 (en) 2017-02-28
TW202005979A (zh) 2020-02-01
US10093711B2 (en) 2018-10-09
BR112015022440B1 (pt) 2022-08-16
SMT201900415T1 (it) 2019-09-09
KR20250002742A (ko) 2025-01-07
PE20151763A1 (es) 2015-12-10
WO2014153063A1 (fr) 2014-09-25
MA38477A1 (fr) 2017-09-29
JP2025066162A (ja) 2025-04-22
CR20200004A (es) 2020-03-11
CA2905141A1 (fr) 2014-09-25
CY1121823T1 (el) 2020-07-31
EP2970441B1 (fr) 2019-03-06
DK2970441T3 (da) 2019-06-03
SI2970423T1 (sl) 2019-08-30
AU2014236281B2 (en) 2018-03-08
UY35454A (es) 2014-09-30
US9546203B2 (en) 2017-01-17
MA38477B1 (fr) 2019-05-31
HK1220695A1 (en) 2017-05-12
CA3149348C (fr) 2023-09-12
TWI687435B (zh) 2020-03-11
ES2737598T3 (es) 2020-01-15
US20170137485A1 (en) 2017-05-18
AU2014236316A1 (en) 2015-10-08
PH12015502051A1 (en) 2016-01-18
IL241622B (en) 2020-09-30
NZ751148A (en) 2021-05-28
MX2015012890A (es) 2015-12-03
SMT201900301T1 (it) 2019-07-11
HUE043488T2 (hu) 2019-08-28
KR102219124B1 (ko) 2021-02-22
JP2016518823A (ja) 2016-06-30
KR102418771B1 (ko) 2022-07-08
LT2970423T (lt) 2019-05-27
HRP20190970T1 (hr) 2019-07-26
PH12015502051B1 (en) 2016-01-18
ME03482B (me) 2020-01-20
PT2970423T (pt) 2019-07-23
CL2015002669A1 (es) 2016-09-09
SG11201507574VA (en) 2015-10-29
EA032863B1 (ru) 2019-07-31
UA119140C2 (uk) 2019-05-10
TWI709572B (zh) 2020-11-11
US20180237489A1 (en) 2018-08-23
MX372880B (es) 2020-07-08
US10829535B2 (en) 2020-11-10
BR112015023145A2 (pt) 2017-11-21
TR201908362T4 (tr) 2019-06-21
KR20230157526A (ko) 2023-11-16
EA201591731A1 (ru) 2016-04-29
JP2023053148A (ja) 2023-04-12
HUE044321T2 (hu) 2019-10-28
PT2970441T (pt) 2019-06-11
MX2015012912A (es) 2015-12-03
KR20150130342A (ko) 2015-11-23
CN105358570B (zh) 2019-11-12
CL2015002686A1 (es) 2016-04-15
US20140343252A1 (en) 2014-11-20
IL241349A0 (en) 2015-11-30
MA49207A1 (fr) 2021-09-30
LT2970441T (lt) 2019-06-10
JP2019058182A (ja) 2019-04-18
AP2015008737A0 (en) 2015-09-30
MX366854B (es) 2019-07-26
JP6480409B2 (ja) 2019-03-13
CY1121767T1 (el) 2020-07-31
US20210094997A1 (en) 2021-04-01
US20170081382A1 (en) 2017-03-23
EP2970441A4 (fr) 2016-11-23
EP2970441A1 (fr) 2016-01-20
TN2015000416A1 (en) 2017-01-03
TW201522366A (zh) 2015-06-16
EA201591766A1 (ru) 2016-02-29
AU2014236316B2 (en) 2018-11-01
CA2906708C (fr) 2022-05-03
TW202115106A (zh) 2021-04-16
SG11201507420UA (en) 2015-10-29
KR20220101009A (ko) 2022-07-18
US9932380B2 (en) 2018-04-03
RS58791B1 (sr) 2019-07-31
CA3149348A1 (fr) 2014-09-25
UY40090A (es) 2023-04-14
CN105358570A (zh) 2016-02-24
KR20150127185A (ko) 2015-11-16
PL2970423T3 (pl) 2019-10-31
EP2970423B1 (fr) 2019-04-24
WO2014153111A3 (fr) 2014-11-13
US20140286898A1 (en) 2014-09-25
JP7227951B2 (ja) 2023-02-22
JP2016514161A (ja) 2016-05-19
BR112015022440A2 (pt) 2017-10-24
CN105143253A (zh) 2015-12-09
IL241349B (en) 2018-08-30
US20240327485A1 (en) 2024-10-03
CA2906708A1 (fr) 2014-09-25

Similar Documents

Publication Publication Date Title
MA49207B1 (fr) Muteines d'interleukine 2 pour la propagation de lymphocytes t regulateurs
EA201792250A1 (ru) Мутеины интерлейкина-2 для роста регуляторных т-клеток
NZ775714A (en) Interleukin-2 muteins for the expansion of t-regulatory cells
AU2019255744A8 (en) IL-15/IL-15Ra heterodimeric Fc fusion proteins and uses thereof
WO2021067863A3 (fr) Protéines de fusion fc hétérodimères d'il-12 ciblées
GB2450056A (en) CD47 Related compositions and methods for treating immunological diseases and disorders
WO2017201432A3 (fr) Interleukine-2 liée à son récepteur il-2rbêta, plate-forme pour améliorer l'activité des cellules tueuses naturelles et des lymphocytes t régulateurs
CL2013001107A1 (es) Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas.
MX421100B (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso
PH12015501796A1 (en) Il-1b inhibitor composition and use thereof
EP4093778A4 (fr) Protéines hétérodimères à mutations fc
WO2019090215A3 (fr) Systèmes à récepteur antigénique chimérique avec ligand dominant négatif
CL2017002553A1 (es) Muteínas de interleuquina 2 para la expansión de células t regulatorias
BR112014017788A2 (pt) proteína de fusão de interferona e de seção fc de imunoglobulina
HK40072936A (en) Recombinant human sialidases, sialidase fusion proteins, and methods of using the same